Table 3.
Cox multivariate analysis of disease-free and overall survival
| |
Recur HR (95% CI) |
P-value |
Death HR (95% CI) |
P-value |
|---|---|---|---|---|
| Mode of BC Detection | ||||
| Screen Detection |
1.00 |
|
1.00 |
|
| Symptomatic |
2.02 (0.97–4.18) |
.059 |
2.68 (0.92–7.77) |
.07 |
|
Age |
|
.21 |
|
.001 |
| <40 |
1.00 |
|
1.00 |
|
| 40–49 |
0.72 (0.34–1.54) |
.42 |
1.24 (0.32–4.93) |
.71 |
| 50–69 |
1.19 (0.62–2.28) |
.63 |
3.61 (1.09–11.99) |
.04 |
| ≥70 |
1.44 (0.67–3.08) |
.35 |
6.56 (1.83–23.47) |
.004 |
|
Tumor size |
|
.12 |
|
.14 |
| T1 |
1.00 |
|
1.00 |
|
| T2 |
1.36 (0.87–2.15) |
.23 |
1.58 (0.86–2.91) |
.11 |
| T3–T4 |
2.03 (1.01–4.06) |
.04 |
2.32 (0.96–5.6) |
.06 |
|
No. of positive Lymph nodes |
|
<.0001 |
|
<.0001 |
| All lymph nodes negative |
1.00 |
|
1.00 |
|
| 1–3 |
2.22 (1.28–3.84) |
.004 |
1.66 (0.77–3.54) |
.19 |
| ≥4 |
5.31 (3.15–8.96) |
<.0001 |
6.09 (3.07–11.96) |
<.0001 |
|
Molecular Subtypes* |
|
<.0001 |
|
.22 |
| Luminal A |
1.00 |
|
1.00 |
|
| Luminal B |
1.46 (0.86–2.47) |
.21 |
1.04 (0.51–2.14) |
.89 |
| Non-Luminal HER2+ |
1.80 (0.97–3.35) |
.06 |
2.23 (1.07–4.67) |
.03 |
| Non Basal-like |
1.75 (0.68–4.53) |
.22 |
1.08 (0.25–4.67) |
.91 |
| Basal-like | 4.72 (2.13–10.46) | <.0001 | 2.06 (0.6–7.05) | .24 |
Abbreviations: BC, breast cancer; D-FS, disease-free survival; OS, overall survival; HR, hazard ratio; * Molecular Subtypes: Luminal A (ER+ and/or PR+) and HER2-; Luminal B (ER+ and/or PR+) and HER2+; Non-Luminal HER2+ (ER- and PR-) and HER2+; Triple Negative (ER-, PR- and HER2-: CK5+ Basal-like; Non Basal-like).